EMulate Therapeutics Announces the Incorporation of Two Wholly Owned Subsidiaries

Written By Kyle Kingma
Kyle Kingma
Previous

EMulate Therapeutics 2021 Year in Review - A Pivotal Year for the Company
Next

EMulate Therapeutics Announces Issuance of Additional U.S. Patent Covering a Therapeutic Device for Cancer and Other Health Indications